Metabolic-Bariatric Surgery Tied to Reduced Risk for Pancreatic Cancer in Those With Obesity
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 9, 2024 -- For individuals with obesity, metabolic-bariatric surgery (MBS) is associated with a reduced risk for pancreatic cancer, especially among those with type 2 diabetes (T2D), according to a review published online Oct. 9 in Diabetes/Metabolism Research and Reviews.
Angeliki M. Angelidi, M.D., Ph.D., from the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and colleagues conducted a systematic review and meta-analysis to examine the impact of MBS on pancreatic cancer risk in individuals with obesity, based on T2D status. Data were included from 12 studies, with 3,711,243 participants.
The researchers found that for both the T2D group and the overall population, pancreatic cancer risk was lower in the MBS group than the non-MBS group (risk ratios, 0.46 and 0.21, respectively); after excluding studies with less than three years of follow-up, the findings were consistent. In individuals without T2D, a favorable impact was also seen (risk ratio, 0.56). When comparing types of MBS versus control, there was a significant difference for sleeve gastrectomy and a nonsignificant improvement for Roux-en-Y gastric bypass.
"Our study showed that ΜBS is associated with decreased pancreatic cancer risk in individuals with obesity irrespective of T2D," the authors write. "Furthermore, our findings suggest that there may be a more pronounced effect of MBS in patients with T2D, highlighting the potential preventive advantages of MBS in this population."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction
THURSDAY, June 26, 2025 -- Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial...
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.